OKYO Pharma to Present at Eyecelerator and ARVO with Urcosimod Phase 2 Data
OKYO Pharma CEO Robert Dempsey will present on corneal and anterior segment disease challenges at Eyecelerator on May 1. CSO Raj Patil will discuss Phase 2 data showing clinically meaningful pain reduction with urcosimod in first-in-human neuropathic corneal pain patients at ARVO on May 5.
1. Upcoming Eyecelerator Presentation
On May 1, 2026, OKYO Pharma CEO Robert J. Dempsey will deliver a five-minute presentation titled “Addressing Unmet Needs in Corneal and Anterior Segment Diseases” in Room 401 at the Eyecelerator conference, outlining the company’s strategy for inflammatory and neuropathic eye conditions.
2. ARVO Presentation of Phase 2 NCP Trial Data
On May 5 at the ARVO Annual Meeting in Denver, CSO Raj Patil will present poster 3461/0044 detailing the first-in-human study of urcosimod in neuropathic corneal pain patients, reporting clinically meaningful pain reduction and quality-of-life improvements.
3. Progress and Next Steps for Urcosimod
Urcosimod is the first investigational therapy with an IND for neuropathic corneal pain and holds FDA Fast Track status; OKYO completed an 18-patient Phase 2 trial with significant pain-reduction endpoints and plans to initiate a 150-patient Phase 2b/3 multiple-dose study in the first half of 2026.